OncoMatch/Clinical Trials/PM8002
PM8002 (BNT327) Clinical Trials
PM8002 (BNT327) is a humanized bispecific antibody targeting PD-L1 and VEGF-A, distinct from PD-1–targeting agents in its checkpoint specificity while sharing the dual immunotherapy-plus-anti-angiogenic rationale. BioNTech acquired Biotheus for $800 million in 2024, securing global rights to PM8002 as a cornerstone of its solid tumor pipeline. Phase 2 data in treatment-naive PD-L1–positive NSCLC showed an objective response rate of approximately 47% with manageable toxicity. Active trials span NSCLC, small-cell lung cancer, triple-negative breast cancer, cervical cancer, and ovarian cancer; eligibility typically requires PD-L1 expression testing and may specify prior platinum exposure or histology.
Check your eligibilityRecruiting PM8002 trials
Ranked by phase and US site count. Filter by your biomarker profile →
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
BioNTech SE
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
BioNTech SE
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
Biotheus Inc.
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
BioNTech SE
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
BioNTech SE
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
PM8002 is under active investigation across multiple tumor types.
How OncoMatch helps you find PM8002 trials
AI reads the protocol
OncoMatch reads the eligibility criteria for every PM8002 trial and extracts structured requirements — biomarkers, stage, prior therapy — from protocol text.
Enter your results
Select your cancer type and mark your biomarker results. Your data never leaves your device. OncoMatch instantly filters to trials you may qualify for.
See your matches
Each trial shows which criteria you meet, which you don't, and which need more information. Bring the shortlist to your oncologist.